What is the story about?
What's Happening?
Slingshot Biosciences has introduced two new products, TruCytes Potency CD20 and CD34 Stem Cell Gating Controls, aimed at improving the reproducibility and standardization of cell therapy and stem cell research. These products are designed to provide consistent potency readouts and eliminate the variability associated with using human stem cells. The new controls comply with FDA guidance and are expected to accelerate research and development in biopharma and diagnostics.
Why It's Important?
The introduction of these new controls addresses a critical need for standardization in cell therapy research, which is often hampered by variability and ethical concerns related to human stem cell use. By providing a reliable alternative, Slingshot Biosciences' products could streamline research processes, reduce costs, and enhance the accuracy of experimental results. This development is particularly significant for the biopharmaceutical industry, where consistent and reproducible data are essential for regulatory approval and commercialization.
AI Generated Content
Do you find this article useful?
